AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4443869 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 4443869 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous phototherapy
Number of subjects: 120
Study 4443869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent phototherapy
Number of subjects: 120
Study 4443869 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 31277885 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (group 1)
Number of subjects: 84
Study 31277885 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (group 2)
Number of subjects: 84
Study 27613888 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB‐EXT with HV
Number of subjects: 34
Study 27613888 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB‐EXT without HV
Number of subjects: 34
Study 27613888 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 34
Study 27613888 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB‐EXT (with or without HV)
Number of subjects: 34
Study 26278685 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanop Plus (10% HA, 0.2% NaF, nano‐HA/fluoride)
Number of subjects: 13
Study 26278685 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Paste Plus (casein phosphopeptide‐amorphous calcium phosphate, 0.2% NaF)
Number of subjects: 13
Study 26278685 — intervention group
Group type: EXPERIMENTAL
Intervention: F (0.2% NaF)
Number of subjects: 13
Study 26278685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 23972353 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pain during working memory test
Number of subjects: 78
Study 23972353 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no pain)
Number of subjects: 78
Study 23972353 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pain followed by working memory test 20 minutes after pain
Number of subjects: 78
Study 22018365 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized axial length (AL) calculation method
Number of subjects: 0
Study 22018365 — intervention group
Group type: COMPARATOR
Intervention: Standard IOL power calculation formulas (Holladay 1, Haigis, SRK/T, Hoffer Q)
Number of subjects: 0
Study 19392579 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxcinod (AZD3582)
Number of subjects: 0
Study 19392579 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study 17445933 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart with metformin 500 mg t.i.d. for 90 days
Number of subjects: 30
Study 17445933 — intervention group
Group type: COMPARATOR
Intervention: Human insulin with metformin 500 mg t.i.d. for 90 days
Number of subjects: 30
Study 15600248 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir (DNA synthesis inhibitor)
Number of subjects: 0
Study 15899652 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (800 mg/day)
Number of subjects: 29
Study 15899652 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study 10602349 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated fat, low-cholesterol dietary intervention
Number of subjects: 202
Study 8621850 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (600 mg orally four times a day for 8 days)
Number of subjects: 10
Study 8621850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8621850 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton
Number of subjects: 10
Study 1742650 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold allergen dose
Number of subjects: 0
Study 1742650 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher allergen dose (x 10 threshold)
Number of subjects: 0
Study 1742650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7139396 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine 0.04 mg.kg‐1 and atropine 0.01 mg.kg‐1
Number of subjects: 60
Study 7139396 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine 0.04 mg.kg‐1 only
Number of subjects: 60
Study 7139396 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 60
Study 29524000 — intervention group
Group type: EXPERIMENTAL
Intervention: OLE in solution (25 g sucrose)
Number of subjects: 0
Study 29524000 — intervention group
Group type: EXPERIMENTAL
Intervention: OLE in capsules or solution (50 g sucrose or glucose)
Number of subjects: 0
Study 29524000 — intervention group
Group type: COMPARATOR
Intervention: OLE (general use)
Number of subjects: 0
Study 29703254 — intervention group
Group type: EXPERIMENTAL
Intervention: CRADLE Vital Sign Alert device and training package
Number of subjects: 204
Study 27164511 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexketoprofen 50mg
Number of subjects: 83
Study 27164511 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1g
Number of subjects: 83
Study 27164511 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol 1g
Number of subjects: 83
Study 27164511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 24531433 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast water therapy (alternating 1 minute 38° C and 1 minute 15° C water immersion)
Number of subjects: 10
Study 24531433 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast showers (alternating 1 minute 38° C and 1 minute 18° C showers)
Number of subjects: 10
Study 24531433 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (seated rest in 20° C)
Number of subjects: 10
Study 24531433 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast water therapy and contrast showers
Number of subjects: 10
Study 21998061 — intervention group
Group type: EXPERIMENTAL
Intervention: CT hypodensities attributed to delayed ischemic neurological deficit
Number of subjects: 413
Study 21998061 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert consensus on CT hypodensities
Number of subjects: 413
Study 21998061 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver variability in attributing CT hypodensities
Number of subjects: 413
Study 20403600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative music for 30 minutes
Number of subjects: 126
Study 20403600 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting in bed)
Number of subjects: 126
Study 18072989 — intervention group
Group type: EXPERIMENTAL
Intervention: ED staff ordered an exercise stress test for the intervention group.
Number of subjects: 231
Study 18072989 — intervention group
Group type: COMPARATOR
Intervention: Control group advised to contact their family physician (FP) to arrange testing.
Number of subjects: 231
Study 16266651 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple spirometry conducted with an automatic, portable, dry spirometer.
Number of subjects: 277
Study 16266651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of spirometry conducted by a doctor or nurse.
Number of subjects: 277
Study 16266651 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cost scenario with a single nurse conducting spirometry.
Number of subjects: 277
Study 16266651 — intervention group
Group type: EXPERIMENTAL
Intervention: Two trained professionals conducting spirometry.
Number of subjects: 277
Study 12047490 — intervention group
Group type: EXPERIMENTAL
Intervention: nabumetone 1000 mg twice daily
Number of subjects: 12
Study 12047490 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg twice daily
Number of subjects: 12
Study 12047490 — intervention group
Group type: COMPARATOR
Intervention: indomethacin 50 mg
Number of subjects: 12
Study 10069268 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood manipulation
Number of subjects: 67
Study 10069268 — intervention group
Group type: COMPARATOR
Intervention: Sad mood manipulation
Number of subjects: 67
Study 10069268 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood manipulation
Number of subjects: 67
Study 10069268 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 67
Study 7673658 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine augmentation of haloperidol
Number of subjects: 40
Study 7673658 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol with placebo
Number of subjects: 40
Study 31878845 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-to-infant skin-to-skin contact for 30 minutes in the first postnatal hour
Number of subjects: 75
Study 31878845 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 75
Study 30691750 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic moist heat around the elbow
Number of subjects: 56
Study 30691750 — intervention group
Group type: COMPARATOR
Intervention: No thermal agent (control)
Number of subjects: 56
Study 30691750 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic cold around the elbow
Number of subjects: 56
Study 29441909 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.3 mg/kg before intubation, continuous perfusion at 50 μg/kg/min during operation)
Number of subjects: 60
Study 29441909 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study 29441909 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 60
Study 25588713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 92
Study 25588713 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 92
Study 24081158 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) (33-50 μg kg(‐1) day(‐1))
Number of subjects: 20
Study 24081158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plc)
Number of subjects: 20
Study 21920668 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (CBT)
Number of subjects: 83
Study 21920668 — intervention group
Group type: COMPARATOR
Intervention: Group Education Intervention (EDU)
Number of subjects: 83
Study 20084879 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of PCV7
Number of subjects: 488
Study 16948824 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-band UVB phototherapy plus oral acyclovir (800 mg five times a day for 10 days); UVB starting at 20 mJ/cm², increasing by 10 mJ/cm² per session, max 100 mJ/cm², 3 times a week for up to 15 sessions.
Number of subjects: 25
Study 16948824 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir (800 mg five times a day for 10 days) only (control group).
Number of subjects: 25
Study 16948824 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB phototherapy for established PHN (more than 3 months after rash onset).
Number of subjects: 25
Study 15256691 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate ingestion (C; n = 23)
Number of subjects: 48
Study 15256691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P; n = 25)
Number of subjects: 48
Study 15256691 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects combined
Number of subjects: 48
Study 15256691 — intervention group
Group type: EXPERIMENTAL
Intervention: Young runners (<50 years)
Number of subjects: 48
Study 15256691 — intervention group
Group type: EXPERIMENTAL
Intervention: Old runners (>=50 years)
Number of subjects: 48
Study 11421836 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of droperidol 15 microg kg(‐1) and ondansetron 100 microg kg(‐1)
Number of subjects: 240
Study 11421836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 240
Study 11421836 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 150 microg kg(‐1)
Number of subjects: 240
Study 11421836 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 25 microg kg(‐1)
Number of subjects: 240
Study 9202616 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (4 months, 5 days/week, 40 minutes/day)
Number of subjects: 35
Study 8287811 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% sodium tetradecyl sulphate (STD)
Number of subjects: 95
Study 8287811 — intervention group
Group type: COMPARATOR
Intervention: 5% ethanolamine oleate (ETH)
Number of subjects: 95
Study 3566859 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin-Pharbita 0.25 mg (Product A)
Number of subjects: 10
Study 3566859 — intervention group
Group type: COMPARATOR
Intervention: Reference drug B (Product B)
Number of subjects: 10
Study 31799993 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of Antidepressant Medication (ADM)
Number of subjects: 292
Study 31799993 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant Medication (ADM) alone
Number of subjects: 292
Study 31799993 — intervention group
Group type: COMPARATOR
Intervention: Phase 1 condition (ADM alone vs ADM plus CBT)
Number of subjects: 292
Study 31428143 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining alpha transcranial alternating current stimulation (alpha-tACS) targeting left M1 at 10 Hz
Number of subjects: 0
Study 31428143 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining beta transcranial alternating current stimulation (beta-tACS) targeting left M1 at 20 Hz
Number of subjects: 0
Study 31428143 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 0
Study 28363586 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diquafosol ophthalmic solution
Number of subjects: 47
Study 28363586 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 47
Study 25248345 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit Agrippal vaccine
Number of subjects: 110
Study 24229408 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficient algorithms for randomly expanding phylogenetic trees
Number of subjects: 0
Study 24229408 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms for calculating distance matrices
Number of subjects: 0
Study 24229408 — intervention group
Group type: EXPERIMENTAL
Intervention: Source code implementation in C++
Number of subjects: 0
Study 24229408 — intervention group
Group type: EXPERIMENTAL
Intervention: Web service availability
Number of subjects: 0
Study 21883001 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematococcus astaxanthin (ASX) 5 mg
Number of subjects: 39
Study 21883001 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematococcus astaxanthin (ASX) 20 mg
Number of subjects: 39
Study 21883001 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematococcus astaxanthin (ASX) 40 mg
Number of subjects: 39
Study 21883001 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-smokers)
Number of subjects: 39
Study 19485993 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme (SMP) in addition to standard care
Number of subjects: 140
Study 19485993 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 140
Study 16428209 — intervention group
Group type: EXPERIMENTAL
Intervention: Early operation (within six weeks of initial assessment)
Number of subjects: 73
Study 16428209 — intervention group
Group type: COMPARATOR
Intervention: Delayed operation (within six months of recruitment)
Number of subjects: 73
Study 12967073 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct resin composite technique (SBMP++ Z100)
Number of subjects: 40
Study 12967073 — intervention group
Group type: EXPERIMENTAL
Intervention: Open sandwich technique (Fuji II LC + SBMP++ Z100)
Number of subjects: 40
Study 10630442 — intervention group
Group type: EXPERIMENTAL
Intervention: L. acidophilus LB
Number of subjects: 73
Study 10630442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 9360340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oresol-R
Number of subjects: 437
Study 9360340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oresol-F
Number of subjects: 437
Study 9360340 — intervention group
Group type: COMPARATOR
Intervention: Oresol-G
Number of subjects: 437
Study 9360340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oresol-K
Number of subjects: 437
Study 1545961 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 21
Study 1545961 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 21
Study 3899198 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (Dex) 15 mg
Number of subjects: 16
Study 3899198 — intervention group
Group type: COMPARATOR
Intervention: Fenfluramine (Fen) 40 mg
Number of subjects: 16
Study 29887334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 0.25 mg
Number of subjects: 61
Study 29887334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 0.125 mg
Number of subjects: 61
Study 29887334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 0.063 mg
Number of subjects: 61
Study 29887334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 0.031 mg
Number of subjects: 61
Study 29887334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (all doses)
Number of subjects: 61
Study 28258931 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 28258931 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 28258931 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 0
Study 25704503 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose MFGM tablets (6.5 g) for 4 weeks
Number of subjects: 32
Study 25704503 — intervention group
Group type: COMPARATOR
Intervention: Whole milk powder for 4 weeks
Number of subjects: 32
Study 23849431 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/day, N=32)
Number of subjects: 69
Study 23849431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=37)
Number of subjects: 69
Study 21496770 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflex Control(®) shoes (RC)
Number of subjects: 29
Study 21496770 — intervention group
Group type: EXPERIMENTAL
Intervention: MBT(®) shoes
Number of subjects: 29
Study 21496770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 29
Study 18655523 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 0.067 mg/kg/day
Number of subjects: 67
Study 18655523 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 0.033 mg/kg/day
Number of subjects: 67
Study 18655523 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 67
Study 16968587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir (14 mg/kg divided BID)
Number of subjects: 318
Study 16968587 — intervention group
Group type: COMPARATOR
Intervention: High-dose amoxicillin/clavulanate (90/6.4 mg/kg divided BID)
Number of subjects: 318
Study 16968587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 318
Study 16968587 — intervention group
Group type: COMPARATOR
Intervention: High-dose amoxicillin/clavulanate
Number of subjects: 318
Study 15523393 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 42
Study 15523393 — intervention group
Group type: COMPARATOR
Intervention: Radiochemotherapy (200 mg/m²/day of intravenous 5-fluorouracil and 5040 cGy of radiotherapy)
Number of subjects: 42
Study 11515713 — intervention group
Group type: EXPERIMENTAL
Intervention: Willow bark extract (Assalix) 240 mg salicin per day (group W240)
Number of subjects: 451
Study 11515713 — intervention group
Group type: EXPERIMENTAL
Intervention: Willow bark extract (Assalix) 120 mg salicin per day (group W120)
Number of subjects: 451
Study 11515713 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments only (group C)
Number of subjects: 451
Study 9791144 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 27
Study 9791144 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg) plus Icatibant (100 microg/kg)
Number of subjects: 27
Study 9791144 — intervention group
Group type: COMPARATOR
Intervention: Losartan (75 mg)
Number of subjects: 27
Study 7842496 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 8
Study 7842496 — intervention group
Group type: EXPERIMENTAL
Intervention: Single case studies with randomized treatment
Number of subjects: 8
Study 2922985 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 22
Study 2922985 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine
Number of subjects: 22
Study 30572467 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Analgesia (LA) using erbium-doped yttrium aluminium garnet (Er:YAG) laser
Number of subjects: 41
Study 30572467 — intervention group
Group type: COMPARATOR
Intervention: Placebo Analgesia (PA)
Number of subjects: 41
Study 30572467 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Analgesia (LA)
Number of subjects: 41
Study 27099247 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing factor (CRF) injection
Number of subjects: 21
Study 27099247 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 21
Study 24560674 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent replication-deficient delNS1-H1N1 influenza virus vaccine (7.7log10TCID50/volunteer)
Number of subjects: 12
Study 24560674 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent replication-deficient delNS1-H1N1 influenza virus vaccine
Number of subjects: 12
Study 24560674 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal wash sample
Number of subjects: 12
Study 22516692 — intervention group
Group type: EXPERIMENTAL
Intervention: AA genotype group
Number of subjects: 29
Study 22516692 — intervention group
Group type: COMPARATOR
Intervention: TT genotype group
Number of subjects: 29
Study 22516692 — intervention group
Group type: EXPERIMENTAL
Intervention: TA genotype group
Number of subjects: 29
Study 20444742 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir 800 mg twice daily for 5 days
Number of subjects: 422
Study 20444742 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir
Number of subjects: 422
Study 20444742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 18091543 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized algorithm based on maximum flow deflection (F(def))
Number of subjects: 14
Study 18091543 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized algorithm based on maximum airway pressure deflection (P(def))
Number of subjects: 14